title: Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel.
abstract: BACKGROUND
  Paclitaxel is used in the treatment of most gynecologic malignancies. It is solubilized in Cremophor EL, a polyoxyethylated castor oil agent responsible for the high rate of paclitaxel-associated hypersensitivity reactions. Abraxane, a newer, Cremophor-free form of albumin bound paclitaxel has demonstrated an activity and an improved toxicity profile in breast and lung cancers.
  
  
  METHODS
  Five patients with gynecologic cancers (2 ovarian, 2 endometrial, and 1 cervical malignancy) received Abraxane after having a hypersensitivity reaction to paclitaxel. All five patients tolerated Abraxane well, experiencing no reactions or major side effects to the drug.
  
  
  CONCLUSIONS
  Abraxane is well tolerated in women with gynecologic cancer who have experienced a paclitaxel-associated hypersensitivity reaction. Further studies are ongoing to determine the clinical activity of Abraxane in the treatment of these malignancies.
authors.affiliation: Department of Gynecology and Obstetrics, The Cleveland Clinic, Cleveland, OH 44195, USA. amanditan@yahoo.com
authors.forename: Amanda N
authors.initials: AN
authors.lastname: Fader
authors.forename: Peter G
authors.initials: PG
authors.lastname: Rose
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000276:immunology; D000369:Aged, 80 and over; D000068196:Albumin-Bound Paclitaxel; D000418:Albumins / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D004342:Drug Hypersensitivity / Q000628:therapy; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D008875:Middle Aged; D017239:Paclitaxel / Q000009:adverse effects* / Q000276:immunology* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000068196:Albumin-Bound Paclitaxel; D000418:Albumins; D000970:Antineoplastic Agents; D017239:Paclitaxel